The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.
U.S. President Joe Biden said the Centers for Disease Control is likely to advise that kids who have not been vaccinated against Covid-19 should wear masks when they return from summer holidays to school in the fall.
A study found potential in a novel gene therapy method to help children born with a rare genetic and neurodegenerative disorder, AADC deficiency.
The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals Inc.’s Trikafta to treat cystic fibrosis in children aged 6 to 11 years old, making the cocktail therapy the first approved treatment for CF in that age group.
Pfizer Inc. will start a large study to test the company’s Covid-19 vaccine in children below 12 years and selected a dosing regime for the clinical trial.
The U.S. Food and Drug Administration approved the expanded use of Alexion Pharmaceuticals Inc.’s Ultomiris (ravulizumab-cwvz) to include children (1 month of age and older) and adolescents with paroxysmal nocturnal hemoglobinuria (PNH).
From free beer to free childcare, President Joe Biden on June 2 touted new efforts to get 70 percent of U.S. adults at least one shot of vaccination against Covid-19 by the July 4 Independence Day holiday.
The U.S. Food and Drug Administration approved Novartis’ blockbuster drug Cosentyx (secukinumab) for pediatric patients aged 6 years and older with moderate-to-severe plaque psoriasis. The new approval for Cosentyx marks the first for a pediatric patient population in the United States.
Months after recovery from mild Covid-19 – when antibody levels in the blood have declined – immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus, researchers reported on May 24 in Nature. And according to a new U.S. study, young children appear to be significant carriers of more contagious variants of the new coronavirus, such as the ones identified in the UK and in California.
Topline results from two of Merck’s Phase III pediatric trials show the company’s investigational 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.